Project Grant HT9425261E220
Award Date 9/15/26
Completion Date 9/14/30
Dollars Obligated $1.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Great Britain, United Kingdom
Similar Awards
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $749,996 to the Institute of Cancer Research: Royal Cancer Hospital (The) on August 1, 2025, under the Military Medical Research and Development program (CFDA 12.420) for the project "BAK-LOSS Lethal Prostate Cancer: Uncovering Therapeutic Vulnerabilities to Deliver New Treatments and Improve Clinical Outcomes." The four-year award, extending through July 31, 2029, supports research conducted in Great...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Institute For Cancer Research a $1,959,353 project grant effective September 1, 2025 through August 31, 2029, under the Military Medical Research and Development program (CFDA 12.420). This award supports clinical research investigating pembrolizumab maintenance therapy following enfortumab vedotin/pembrolizumab induction treatment in front-line metastatic urothelial carcinoma. The research will be conducted at the...
- The federal Project Grant award in the amount of $499,999.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), funds research by the Institute of Cancer Research: Royal Cancer Hospital (The) to study the interplay of molecular and spatial architectures with clinical states in prostate cancer. The research project aims to make discoveries that defeat cancer through innovative biomedical research. As a subawardee, the Institute of...
- This federal Project Grant award of $299,999.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is funding research at the Institute of Cancer Research: Royal Cancer Hospital (The) in the United Kingdom. The award aims to enhance the efficacy of BH3 mimetics, a class of cancer therapeutic drugs, to induce apoptosis (programmed cell death) in lethal prostate cancer. The performance period for this award is June 1, 2024 through May 31, 2026. As a...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $352,000 under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research for the project period September 1, 2025, through August 31, 2027. The award supports research focused on augmenting the in vivo efficacy of a novel lanosterol synthase inhibitor in glioblastoma treatment. This research aligns with the DHA's mission to transform healthcare for service...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $1.424 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded August 1, 2025, with a performance period through July 31, 2029. The award supports research to expand the targetable tumor antigen repertoire of renal cell carcinoma, positioning the work within DHA's broader portfolio of hypothesis-driven biomedical research...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $2.0 million Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) awarded on September 30, 2026, with a completion date of September 29, 2030. The award supports the Prostate Cancer Clinical Trials Consortium, which delivers clinical trial coordination, patient enrollment, and research management services focused on prostate cancer therapies relevant to...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Sloan-Kettering Institute for Cancer Research a $750,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective October 1, 2026, through April 30, 2029. The award supports research titled "Eliminating TREX1 to Restore Immune Control in Triple-Negative Breast Cancer," which focuses on investigating immunological mechanisms in breast cancer treatment. This research...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The University of Manchester $326,993 under the Military Medical Research and Development program (CFDA 12.420) for a two-year project running from July 1, 2025 through June 30, 2027. The project, titled "Dissecting the Role of Germline ATM Loss in the Evolution of Aggressive Localized Prostate Cancer," focuses on advancing understanding of prostate cancer genetics through translational research. This award...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded Sloan-Kettering Institute for Cancer Research a $559,998 Project Grant on June 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct research on therapeutic targeting of RNA processing to enhance anti-melanoma immunotherapy. The two-year project, concluding May 31, 2028, supports investigator-initiated biomedical research designed to advance medical solutions relevant to Service Member...